Posted inNews and Updates
Record-Breaking Ebola Clinical Trial Begins in DR Congo
A groundbreaking clinical trial has begun in the DRC to test advanced Ebola treatments. Discover how this study aims to lower mortality rates worldwide.
Posted inNews and Updates
Denecimig Shows Consistent Efficacy in Hemophilia A Patients
New trial data shows denecimig offers consistent safety and efficacy for hemophilia A patients across all age groups. Learn the latest clinical findings.
Posted inNews and Updates
Maharashtra FDA Recalls Cadila Pharma’s Aciloc Over Branding
The Maharashtra FDA has ordered a recall of Cadila Pharma’s Aciloc worth Rs 2.45 crore due to deceptive branding. Learn the details behind the major move.
Posted inNews and Updates
Marksans Pharma Expands EU Reach With ABCnow Acquisition
Marksans Pharma to acquire German-based ABCnow GmbH, aiming to expand its EU market presence and streamline drug distribution and regulatory operations.
Posted inNews and Updates
Beyond GLP-1: Could GLP-3 Drugs Revolutionize Weight Loss?
A new class of GLP-3 drugs is showing significant promise in Phase 3 trials for weight loss and diabetes. Learn how this breakthrough may reshape metabolic care.
Posted inNews and Updates
New GLP-1 Implant Could Revolutionize Long-Term Weight Loss
A new miniature GLP-1 implant aims to simplify weight loss maintenance, offering a consistent alternative to injections. Discover the future of obesity care.
Posted inNews and Updates
AstraZeneca Pipeline Under Scrutiny After Clinical Trial Flop
AstraZeneca’s latest clinical trial failure triggers industry-wide concerns about pipeline valuation and the stability of its high-stakes drug portfolio.
Posted inNews and Updates
FDA Approves First Treatment for Brain Injury-Related Obesity
The FDA has approved the first targeted therapy for hypothalamic obesity caused by brain injury, offering new hope for patients with metabolic disorders.
Posted inNews and Updates
Davenport University and Hurley Medical Center Form Pact
Davenport University and Hurley Medical Center launch a new scholarship partnership to tackle staffing shortages and boost local nursing and health careers.
Posted inNews and Updates
Q32 Bio Sets Phase 2a Results for Bempikibart Study
Q32 Bio is set to unveil 36-week Phase 2a trial results for bempikibart, a potential breakthrough therapy targeting the IL-7Rα pathway for autoimmune care.